Back to Results
First PageMeta Content
Vaccines / Acetamides / Neuraminidase inhibitors / Pandemics / Epidemiology / Influenza vaccine / Influenza pandemic / Transmission and infection of H5N1 / Zanamivir / Influenza / Medicine / Health


Purple Paper • Issue No. 21 • NovemberKey Points • All licensed formulations of the pH1N1 vaccine were uniformly immunogenic, having exceeded all regulatory criteria after a single dose in adults
Add to Reading List

Document Date: 2010-12-06 12:13:45

Open Document

File Size: 197,02 KB

Share Result on Facebook

City

Charlottesville / Keystone / London / /

Company

Novartis / GlaxoSmithKline / Sanofi / Zhejiang Tianyuan Biopharmaceutical Company / Wellcome Trust / Baxter / /

Continent

Europe / North America / /

Country

Netherlands / Mongolia / Egypt / Thailand / France / Japan / Brazil / Canada / United Kingdom / China / India / Germany / Mexico / Serbia / Iran / Guinea / Indonesia / Azerbaijan / United States / South Korea / Ireland / /

Currency

USD / /

Facility

the Netherlands Vaccine Institute / Serum Institute of India / Erasmus Medical Centre / University of Virginia / Institute of Molecular Virology / /

IndustryTerm

pharmaceutical agents / communicable disease prevention / vaccine production protocol / pharmaceutical interventions / country vaccine manufacturers / pharmaceutical and non-pharmaceutical interventions / lactose drug carrier / adjuvant systems / injection site / non-pharmaceutical interventions / technology hub / vector delivery systems / health care system infrastructure / public health services / influenza production technologies / treatment of HIV / host machinery / technology / high media coverage / vaccine technologies / /

MedicalCondition

HIV / seasonal influenza A / e.g. hives / oseltamivir-resistant influenza viruses / sterility / universal influenza A / anaphylaxis / severe seasonal influenza disease / large-scale infectious disease / highyield influenza / illness / live attenuated influenza vaccine / asthma / e.g. diarrhea / pneumonia / oseltamivir-resistant influenza A / amantadine-sensitive influenza A / seasonal influenza / uncomplicated and severe seasonal influenza disease / chills / influenza A / Narcolepsy / muscle pain / uncomplicated influenza / fever / vomiting / highly pathogenic influenza A/H5N1 / Allergic reactions / infection / rash / headache / strain / nausea / AS03- and AF03adjuvanted H5N1 influenza / communicable disease / fatigue / dangerous influenza virus / influenza / bronchospasm / influenza disease / different influenza / chronic obstructive pulmonary disease / each influenza / pain / mild-tomoderate disease / angioedema / pneumonic disease / Pandemic influenza / laboratory-confirmed infection / infectious diseases / seasonal influenza A/H1N1 / severe pH1N1 disease / Guillain Barré syndrome / /

MedicalTreatment

drug carrier / immunizations / vaccination / Immunization / renal replacement therapies / mechanical ventilation / organ transplant / /

Organization

World Health Organization / University of Virginia / School of Medicine / Department of Virology / Serum Institute of India / National Center for Immunization and Respiratory Diseases / Institute of Molecular Virology / Westfälische Wilhelms-Universität Münster / Erasmus Medical Centre in Rotterdam / Government Pharmaceutical Organization of Thailand / Centers for Disease Control and Prevention / the Netherlands Vaccine Institute / United Nations / Influenza Division / Department of Immunization / Vaccines and Biologicals / Institute of Molecular Virology at Westfälische Wilhelms-Universität Münster / /

Person

Albert Osterhaus / Ban Ki-moon / David Wood / Stephan Ludwig / Frederick Hayden / Margaret Chan / Nancy Cox / /

Position

Director General / Major / Secretary General / /

Product

Tamiflu / AS03 / ribavirin / Vero cell system / RELENZA / Vero / /

ProvinceOrState

Virginia / Colorado / /

Technology

siRNA / influenza production technologies / recombination / Antibodies / vaccine production protocol / /

SocialTag